Table 2 BiTE clinical trials
From: Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Trial | Structure | Outcomes | Adverse effects | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Agent | Trial ID + references | Status | Phase | Study population | Enrollment (N) | MM Cell target | T Cell Ligand | ORR (%) | MEDIAN PFS (months) | Grade ≥ 3 CRS (%) | Grade 3 NTX (%) |
AMG 420 (pacanalotamab, BI 836,909) | NCT03836053 | Active, not recruiting | 1 | RRMM | 47 | BCMA | CD3 | NA | NA | NA | NA |
AMG 420 (pacanalotamab, BI 836,909) | NCT02514239 [132] | Completed | 1 | RRMM | 42 | BCMA | CD3 | 70 | 23.5 | 2 | 4 |
AMG 701 (pavurutamab) | NCT04998747 (ProxiMMity-1) | Not yet recruiting | 1 | RRMM | 47 | BCMA | CD3 | NA | NA | NA | NA |
elranatamab (PF-06863135) | NCT03269136 (MagnetisMM-1) [133] | Active, not recruiting | 1 | RRMM | 90 | BCMA | CD3 | 75 | Not published | 0 | 0 |
elranatamab (PF-06863135) | NCT04798586 (MagnetisMM-2) | Active, not recruiting | 1 | RRMM | 4 | BCMA | CD3 | NA | NA | NA | NA |
teclistamab (JNJ-64007957) | NCT03145181 (MajesTEC-1) [134] | Recruiting | 1 | RRMM | 204 | BCMA | CD3 | 67 | Not published | 0 | 3 |
teclistamab (JNJ-64007957)  + anticancer drugs | NCT04722146 | Recruiting | 1 | RRMM | 140 | BCMA | CD3 | NA | NA | NA | NA |
teclistamab and talquetamab | NCT04586426 (RedirecTT-1) | Recruiting | 1 | RRMM | 56 | BCMA and GPRC5D | CD3 | NA | NA | NA | NA |
teclistamab (or talquetamab)  + daratumumab | NCT04108195 (TRIMM-2) [135] | Recruiting | 1 | RRMM | 200 | BCMA or GPRC5D | CD3 | 78 | Not published | 0 | 0 |
alnuctamab (CC-93269, EM901) | NCT03486067 [136] | Recruiting | 1 | RRMM | 175 | BCMA | CD3 | 83 | Not published | 5 | 0 |
TNB-383B | NCT03933735 [137] | Recruiting | 1 | RRMM | 169 | BCMA | CD3 | 52 | Not published | 0 | 0 |
WVT078 | NCT04123418 | Recruiting | 1 | RRMM | 90 | BCMA | CD3 | NA | NA | NA | NA |
REGN5458 | NCT05137054 | Not yet recruiting | 1 | RRMM | 256 | BCMA | CD3 | NA | NA | NA | NA |
teclistamab (JNJ-64007957) | NCT04696809 | Recruiting | 1/2 | RRMM | 33 | BCMA | CD3 | NA | NA | NA | NA |
AMG 701 (pavurutamab)  + pomalidomide | NCT03287908 [138] | Recruiting | 1/2 | RRMM | 408 | BCMA | CD3 | 82 | Not published | 7 | 0 |
elranatamab (PF-06863135)  + gamma-secretase inhibitor | NCT05090566 (MagnetisMM-4) | Recruiting | 1/2 | RRMM | 65 | BCMA | CD3 | NA | NA | NA | NA |
elranatamab (PF-06863135) | NCT05014412 (MagnetisMM-9) | Recruiting | 1/2 | RRMM | 76 | BCMA | CD3 | NA | NA | NA | NA |
REGN5458 | NCT03761108 [139] | Recruiting | 1/2 | RRMM | 292 | BCMA | CD3 | 60 | Not published | 0 | 0 |
REGN5459 | NCT04083534 | Active, not recruiting | 1/2 | RRMM | 43 | BCMA | CD3 | NA | NA | NA | NA |
EMB-06 | NCT04735575 | recruiting | 1/2 | RRMM | 66 | BCMA | CD3 | NA | NA | NA | NA |
teclistamab (JNJ-64007957) | NCT04557098 (MajesTEC-1) [140] | Recruiting | 2 | RRMM | 192 | BCMA | CD3 | 65 | Not yet reached | 0 | 0 |
elranatamab (PF-06863135) | NCT04649359 (MagnetisMM-3) | Active, not recruiting | 2 | RRMM | 180 | BCMA | CD3 | NA | NA | NA | NA |
elranatamab (PF-06863135) | NCT05228470 (MagnetisMM-8) | Recruiting | 2 | RRMM | 36 | BCMA | CD3 | NA | NA | NA | NA |
talquetamab (JNJ-64407564) | NCT03399799 [75] | Recruiting | 1 | RRMM | 260 | GPRC5D | CD3 | 63 | Not yet published | 4 | 0 |
talquetamab (JNJ-64407564)  + anticancer drugs | NCT05050097 | Recruiting | 1 | RRMM | 176 | GPRC5D | CD3 | NA | NA | NA | NA |
talquetamab (JNJ-64407564) | NCT04773522 | Recruiting | 1 | RRMM | 9 | GPRC5D | CD3 | NA | NA | NA | NA |
talquetamab (JNJ-64407564) | NCT04634552 | Recruiting | 2 | RRMM | 320 | GPRC5D | CD3 | NA | NA | NA | NA |
blinatumomab | NCT03173430 | Terminated | 1 | RRMM | 6 | CD19 | CD3 | NA | NA | NA | NA |
AMG 424 | NCT03445663 | Terminated | 1 | RRMM | 27 | CD38 | CD3 | NA | NA | NA | NA |
Y150 | NCT05011097 | Recruiting | 1 | RRMM | 75 | CD38 | CD3 | NA | NA | NA | NA |
GBR1342 (ISB 1342) | NCT03309111 | Recruiting | 1 | RRMM | 197 | CD38 | CD3 | NA | NA | NA | NA |
cevostamab (BFCR4350A, RG6160) | NCT04910568 (CAMMA 1) | Recruiting | 1 | RRMM | 120 | FcRH5 | CD3 | NA | NA | NA | NA |
cevostamab (BFCR4350A, RG6160) | NCT03275103 (GO39775) [141] | Recruiting | 1 | RRMM | 300 | FcRH5 | CD3 | 52 | Not yet reached | 2 | 0 |